Protagenic Therapeutics, Inc. Files 10-K/A Amendment

TL;DR

<b>Protagenic Therapeutics, Inc. filed a 10-K/A amendment for the fiscal year ending December 31, 2023.</b>

AI Summary

Protagenic Therapeutics, Inc.\new (PTIXW) filed a Amended Annual Report (10-K/A) with the SEC on May 14, 2024. Protagenic Therapeutics, Inc. filed a 10-K/A amendment on May 14, 2024. The filing pertains to the fiscal year ending December 31, 2023. The company's previous names include Atrinsic, Inc., NEW MOTION, INC., and MPLC, Inc. Protagenic Therapeutics, Inc. is incorporated in Delaware. The company's business and mailing address is 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010.

Why It Matters

For investors and stakeholders tracking Protagenic Therapeutics, Inc.\new, this filing contains several important signals. This amendment provides updated financial and operational information for the fiscal year 2023, which is crucial for investors to assess the company's current standing. Understanding the company's history, including its former names and incorporation details, offers context for its evolution and corporate structure.

Risk Assessment

Risk Level: — Protagenic Therapeutics, Inc.\new shows moderate risk based on this filing. The filing is an amendment (10-K/A) which typically indicates corrections or additions to a previously filed document, suggesting a need for updated information rather than new material events.

Analyst Insight

Review the specific changes and additions in the 10-K/A filing to understand any material updates to Protagenic Therapeutics' financial position or business operations for FY2023.

Key Players & Entities

• Protagenic Therapeutics, Inc. (company) — Filer name
• 2024-05-14 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end
• Atrinsic, Inc. (company) — Former company name
• NEW MOTION, INC. (company) — Former company name
• MPLC, Inc. (company) — Former company name
• DE (jurisdiction) — State of incorporation
• 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010 (address) — Business address

FAQ

Industry Context

Protagenic Therapeutics operates in the pharmaceutical preparations industry.

Regulatory Implications

The filing is a 10-K/A, an amendment to the annual report, filed under the Securities Exchange Act of 1934.

What Investors Should Do

1. Analyze the specific amendments made in the 10-K/A filing.
2. Verify the accuracy of financial data presented for the fiscal year 2023.
3. Understand the company's corporate history and structure through its former names and incorporation details.

Key Dates

• 2024-05-14: 10-K/A Filing — Amendment filed for the fiscal year ending 2023-12-31.
• 2023-12-31: Fiscal Year End — Reporting period for the financial data in the 10-K/A.

Year-Over-Year Comparison

This is an amended filing (10-K/A), indicating updates or corrections to a previously submitted annual report for the fiscal year 2023.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 , PTIX Nasdaq Capital Market Commo
• $2.03 — eported on the Nasdaq Capital Market of $2.03 was approximately $ 8,791,847 . As of
• $0 — he registrant's common stock, par value $0.0001, issued and outstanding. DOCUMEN

Filing Documents

• form10-ka.htm (10-K/A) — 1480KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 8KB
• form10-ka_001.jpg (GRAPHIC) — 22KB
• form10-ka_002.jpg (GRAPHIC) — 12KB
• form10-ka_003.jpg (GRAPHIC) — 20KB
• form10-ka_004.jpg (GRAPHIC) — 17KB
• 0001493152-24-019018.txt (&nbsp;) — 5420KB
• ptix-20231231.xsd (EX-101.SCH) — 34KB
• ptix-20231231_cal.xml (EX-101.CAL) — 46KB
• ptix-20231231_def.xml (EX-101.DEF) — 176KB
• ptix-20231231_lab.xml (EX-101.LAB) — 346KB
• ptix-20231231_pre.xml (EX-101.PRE) — 272KB
• form10-ka_htm.xml (XML) — 568KB

Business

Business 6 Item 1A Risk Factors 20 Item 1B Unresolved Staff Comments 41 Item 1C Cybersecurity 41 Item 2

Properties

Properties 41 Item 3

Legal Proceedings

Legal Proceedings 41 Item 4 Mine Safety Disclosures 41 PART II 42 Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 42 Item 6 [Reserved] 42 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 42 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 45 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 45 Item 9A

Controls and Procedures

Controls and Procedures 46 Item 9B Other Information 47 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 48 PART III 48 Item 10 Directors, Executive Officers and Corporate Governance 48 Item 11

Executive Compensation

Executive Compensation 54 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 56 Item 13 Certain Relationships and Related Transactions, and Director Independence 65 Item 14 Principal Accountant Fees and Services 67 PART IV 67 Item 15 Exhibits and Financial Statement Schedules 67

SIGNATURES

SIGNATURES 70 2 EXPLANATORY NOTE On April 23, 2024, Protagenic Therapeutics, Inc. (the "Company") filed Amendment No. 1 ( "Amendment No. 1") to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission (the "SEC") on April 1, 2023 (the "Original Filing") to correct an inadvertent error in the Original Filing. Exhibit 32.1 (Certification Pursuant To 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002) was inadvertently omitted from the filed version of the Original Filing. This Amended 10-K ("Amendment No. 2") now amends the Exhibit Index required by Part IV, Item 15 of the Annual Report in order to, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, file currently dated certifications of the Company's principal executive officer and principal financial officer as Exhibits 31.1 and 31.2 (which were not currently dated in Amendment No. 1) as well as a currently dated Exhibit 32.1. No attempt has been made in this Amendment No. 2 to otherwise modify or update the other disclosures presented in the Original Filing. This Amendment No. 2 does not reflect events occurring after the Original Filing (i.e., those events occurring after April 1, 2024) or modify or update those disclosures that may be affected by subsequent events. Such subsequent matters are addressed in subsequent reports filed with the SEC. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company's other filings with the SEC. 3 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with

View Full Filing

View this 10-K/A filing on SEC EDGAR